Telomir Pharmaceuticals (NASDAQ: TELO) reported new research findings from The Ohio State University College of Veterinary Medicine demonstrating that its lead compound, Telomir-Zn, produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, conducted under the direction of Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. According to the company, the results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma.
Osteosarcoma is a type of bone cancer that affects both humans and dogs, with canine cases often serving as a valuable model for the human disease due to similarities in biology and progression. The finding that Telomir-Zn inhibits growth in both species’ cell lines at comparable low concentrations suggests a potential cross-species applicability that could accelerate research and development. Telomir is in discussions with The Ohio State University College of Veterinary Medicine and assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could support both veterinary development and translational advancement toward human osteosarcoma, offering a dual-purpose pathway that may reduce the time and cost typically associated with oncology drug development.
Despite the promising osteosarcoma data, Telomir said its immediate focus remains its triple-negative breast cancer program, which is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared Investigational New Drug (IND) application for advanced or metastatic TNBC. The company’s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation. It has received IND clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer.
The new osteosarcoma findings add to the growing body of preclinical evidence for Telomir-Zn and highlight the potential of repurposing or expanding the compound’s application beyond its initial cancer target. If successful, the canine osteosarcoma study could provide valuable data to inform human trials, leveraging the naturally occurring disease in dogs as a translational model. This approach aligns with broader efforts in comparative oncology, where veterinary and human research converge to accelerate therapeutic development.
For investors and industry observers, the announcement underscores Telomir’s commitment to exploring multiple avenues for its lead asset while maintaining momentum on its primary breast cancer program. The company’s ability to advance Telomir-Zn across different cancer types could broaden its market potential and attract additional partnership or funding opportunities. However, as with any early-stage research, significant further testing is required before any clinical application in humans or animals can be realized. The next steps, including the design and timing of a potential in vivo study, will be closely watched by stakeholders.
To view the full press release, visit https://nnw.fm/laeGH. The latest news and updates relating to TELO are available in the company’s newsroom at https://nnw.fm/TELO.
